Intravenous Levetiracetam in the Acute Management of Seizures

Intravenous Levetiracetam in the Acute Management of Seizures in Epilepsy

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000293369

Enrollment

Registered

2008-06-12

Start date

2008-06-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To examine the effectiveness and tolerability of Intravenous Levetiracetam in the acute seizure setting

Interventions

Intravenous Levetiracetam will be administered in case of acute seizure (1000 mg over 5 minutes), for 1 dose only. Subjects will be observed and followed-up for the next 24 hrs following intravenous levetiracetam injection. Electroencephalographic recordings will be reviewed and subjects will be asked about adverse effects at 1, 12 and 24 hrs after intravenous administration of the agent.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Epilepsy patients admitted for pre-surgical work-up at Monash Medical Centre with occurrence of acute seizures during epilepsy monitoring

Exclusion criteria

Women who are pregnanat or are considering pregnancy, lactation, moderate to severe renal dysfunction

Outcome results